KR20030092044A - 면역증강성 뮤신 펩티드 - Google Patents
면역증강성 뮤신 펩티드 Download PDFInfo
- Publication number
- KR20030092044A KR20030092044A KR10-2003-7012901A KR20037012901A KR20030092044A KR 20030092044 A KR20030092044 A KR 20030092044A KR 20037012901 A KR20037012901 A KR 20037012901A KR 20030092044 A KR20030092044 A KR 20030092044A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- peptide
- sec
- tumor
- muc1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 123
- 108010063954 Mucins Proteins 0.000 title description 3
- 102000015728 Mucins Human genes 0.000 title description 3
- 230000002766 immunoenhancing effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 58
- 230000028993 immune response Effects 0.000 claims abstract description 32
- 229920001184 polypeptide Polymers 0.000 claims abstract description 26
- 229960005486 vaccine Drugs 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 16
- 241000124008 Mammalia Species 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 69
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 67
- 102100034256 Mucin-1 Human genes 0.000 claims description 67
- 239000000427 antigen Substances 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 12
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 25
- 238000011282 treatment Methods 0.000 abstract description 8
- 101100346929 Homo sapiens MUC1 gene Proteins 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 102000057860 human MUC1 Human genes 0.000 abstract description 6
- 230000002163 immunogen Effects 0.000 abstract description 6
- 102000014914 Carrier Proteins Human genes 0.000 abstract description 3
- 108010078791 Carrier Proteins Proteins 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 137
- 241000699670 Mus sp. Species 0.000 description 53
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 38
- 210000004881 tumor cell Anatomy 0.000 description 36
- 102000001708 Protein Isoforms Human genes 0.000 description 31
- 108010029485 Protein Isoforms Proteins 0.000 description 31
- 230000000694 effects Effects 0.000 description 23
- 238000002255 vaccination Methods 0.000 description 20
- 210000004988 splenocyte Anatomy 0.000 description 19
- 230000004614 tumor growth Effects 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 17
- 230000012010 growth Effects 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 239000002671 adjuvant Substances 0.000 description 13
- 230000003013 cytotoxicity Effects 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- 229930193140 Neomycin Natural products 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- 229960004927 neomycin Drugs 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 230000002519 immonomodulatory effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 6
- 230000005748 tumor development Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000002434 immunopotentiative effect Effects 0.000 description 5
- 201000008968 osteosarcoma Diseases 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 102000004503 Perforin Human genes 0.000 description 3
- 108010056995 Perforin Proteins 0.000 description 3
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- DJZCTUVALDDONK-HQMSUKCRSA-N concanamycin A Chemical compound O1C(=O)\C(OC)=C\C(\C)=C\[C@@H](C)[C@@H](O)[C@@H](CC)[C@@H](O)[C@H](C)C\C(C)=C\C=C\[C@H](OC)[C@H]1[C@@H](C)[C@@H](O)[C@H](C)[C@]1(O)O[C@H](\C=C\C)[C@@H](C)[C@H](O[C@@H]2O[C@H](C)[C@@H](OC(N)=O)[C@H](O)C2)C1 DJZCTUVALDDONK-HQMSUKCRSA-N 0.000 description 3
- DJZCTUVALDDONK-UHFFFAOYSA-N concanamycin A Natural products O1C(=O)C(OC)=CC(C)=CC(C)C(O)C(CC)C(O)C(C)CC(C)=CC=CC(OC)C1C(C)C(O)C(C)C1(O)OC(C=CC)C(C)C(OC2OC(C)C(OC(N)=O)C(O)C2)C1 DJZCTUVALDDONK-UHFFFAOYSA-N 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 229930192851 perforin Natural products 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 101150114927 MUC1 gene Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000244160 Echinococcus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000012480 LAL reagent Substances 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 241000282346 Meles meles Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 101100211688 Mycobacterium leprae (strain TN) ML0287 gene Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- FRZJZRVZZNTMAW-UHFFFAOYSA-N n,n-diethyl-3-(hydroxymethyl)benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(CO)=C1 FRZJZRVZZNTMAW-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28013701P | 2001-04-02 | 2001-04-02 | |
| US60/280,137 | 2001-04-02 | ||
| PCT/US2002/010155 WO2002078607A2 (en) | 2001-04-02 | 2002-04-02 | Mucin peptide with immunoenhancing properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20030092044A true KR20030092044A (ko) | 2003-12-03 |
Family
ID=23071833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2003-7012901A Withdrawn KR20030092044A (ko) | 2001-04-02 | 2002-04-02 | 면역증강성 뮤신 펩티드 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7285282B2 (enExample) |
| EP (1) | EP1372691B1 (enExample) |
| JP (2) | JP4223813B2 (enExample) |
| KR (1) | KR20030092044A (enExample) |
| CN (1) | CN1525864A (enExample) |
| AT (1) | ATE376836T1 (enExample) |
| BR (1) | BR0208771A (enExample) |
| CA (1) | CA2443045A1 (enExample) |
| DE (1) | DE60223232T2 (enExample) |
| NZ (1) | NZ528234A (enExample) |
| WO (1) | WO2002078607A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1301267C (zh) * | 2005-06-21 | 2007-02-21 | 中国人民解放军军事医学科学院附属医院 | Muc1粘蛋白的一个模拟表位肽及其编码dna与应用 |
| EP2037966A2 (en) * | 2006-05-11 | 2009-03-25 | Ghent University | Sialoadhesin-related compositions and methods |
| CN112574283B (zh) * | 2020-12-07 | 2022-07-05 | 湖北文理学院 | 一种人muc1特异性结合多肽及其提取方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2668064B1 (fr) * | 1990-10-23 | 1994-12-16 | Transgene Sa | Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne. |
-
2002
- 2002-04-02 US US10/113,800 patent/US7285282B2/en not_active Expired - Fee Related
- 2002-04-02 AT AT02757916T patent/ATE376836T1/de not_active IP Right Cessation
- 2002-04-02 KR KR10-2003-7012901A patent/KR20030092044A/ko not_active Withdrawn
- 2002-04-02 CA CA002443045A patent/CA2443045A1/en not_active Abandoned
- 2002-04-02 JP JP2002576876A patent/JP4223813B2/ja not_active Expired - Fee Related
- 2002-04-02 WO PCT/US2002/010155 patent/WO2002078607A2/en not_active Ceased
- 2002-04-02 DE DE60223232T patent/DE60223232T2/de not_active Expired - Fee Related
- 2002-04-02 NZ NZ528234A patent/NZ528234A/en unknown
- 2002-04-02 EP EP02757916A patent/EP1372691B1/en not_active Expired - Lifetime
- 2002-04-02 BR BR0208771-5A patent/BR0208771A/pt not_active IP Right Cessation
- 2002-04-02 CN CNA028077784A patent/CN1525864A/zh active Pending
-
2004
- 2004-08-04 US US10/910,612 patent/US20050095675A1/en not_active Abandoned
-
2005
- 2005-04-05 JP JP2005109271A patent/JP2005247861A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2443045A1 (en) | 2002-10-10 |
| WO2002078607A2 (en) | 2002-10-10 |
| US7285282B2 (en) | 2007-10-23 |
| EP1372691B1 (en) | 2007-10-31 |
| DE60223232T2 (de) | 2008-08-14 |
| JP2004532018A (ja) | 2004-10-21 |
| WO2002078607A3 (en) | 2003-03-27 |
| CN1525864A (zh) | 2004-09-01 |
| EP1372691A4 (en) | 2005-11-09 |
| US20030166853A1 (en) | 2003-09-04 |
| NZ528234A (en) | 2006-01-27 |
| US20050095675A1 (en) | 2005-05-05 |
| JP4223813B2 (ja) | 2009-02-12 |
| EP1372691A2 (en) | 2004-01-02 |
| JP2005247861A (ja) | 2005-09-15 |
| BR0208771A (pt) | 2004-07-06 |
| ATE376836T1 (de) | 2007-11-15 |
| DE60223232D1 (de) | 2007-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2318898T3 (es) | Antigenos tumorales basados en el producto del gen wt1 supresor de tumor. | |
| TWI611810B (zh) | 具有較高碳水化合物抗原密度之疫苗及其醫藥組成合物 | |
| ES2373055T3 (es) | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. | |
| JP2001510806A (ja) | ワクチン用アジュバントとしてのｍｈｃクラスｉｉリガンドの使用および癌治療におけるｌａｇ−３の使用 | |
| US10487143B2 (en) | Vaccines against HER3 antigens and methods of using the same | |
| Mandal-Ghosh et al. | Neem leaf preparation enhances Th1 type immune response and anti-tumor immunity against breast tumor associated antigen | |
| JP2023109840A (ja) | 新しいｐｄｌ２化合物 | |
| JP2025179041A (ja) | 帯状疱疹ｍＲＮＡワクチン及びその調製方法と使用 | |
| KR100378901B1 (ko) | 사람위암에대한면역반응을유도할수있는펩타이드및이러한펩타이드를함유하는사람위암의예방또는치료용제제 | |
| CZ20011521A3 (cs) | Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek | |
| KR20030092044A (ko) | 면역증강성 뮤신 펩티드 | |
| Arancibia et al. | Hemocyanins in the immunotherapy of superficial bladder cancer | |
| JP2010515670A (ja) | 癌治療のための、手術、化学療法または放射線療法と併用した免疫療法におけるｍａｇｅａ３−プロテインｄ融合抗原の使用 | |
| JP7585480B2 (ja) | Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原 | |
| Herbert et al. | A unique mucin immunoenhancing peptide with antitumor properties | |
| AU2002307032A1 (en) | Mucin peptide with immunoenhancing properties | |
| EP4112636A1 (en) | Tumor immune enhancer, and preparation method therefor and application thereof | |
| Apostolopoulos | Peptides and Peptide Mimetics: Can they be used for tumour immunotherapy? | |
| Thompson | IMMUNE RECOGNITION OF TUMOR-ASSOCIATED MUC1 IS ACHIEVED BY A FULLY SYNTHETIC ABERRANTLY GLYCOSYLATED MUC1 TRIPARTITE VACCINE | |
| WO2005083062A1 (ja) | 細胞ワクチン | |
| CZ20004065A3 (cs) | Peptidy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20031001 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |